Dorzolamide
Cosopt, Dorzolamide (dorzolamide) is a small molecule pharmaceutical. Dorzolamide was first approved as Trusopt on 1994-12-09. It is used to treat open-angle glaucoma in the USA. It is known to target carbonic anhydrase 12, carbonic anhydrase 1, carbonic anhydrase 7, and carbonic anhydrase 14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Combinations
Cosopt (generic drugs available since 2008-10-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dorzolamide hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRUSOPT | Merck Sharp & Dohme | N-020408 DISCN | 1994-12-09 | 1 products, RLD |
Hide discontinued
Dorzolamide hydrochloride
+
Timolol maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COSOPT | Thea Pharma | N-020869 RX | 1998-04-07 | 1 products, RLD, RS |
| COSOPT PF | Thea Pharma | N-202667 RX | 2012-02-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| brim-dor pf | unapproved drug other | 2018-05-08 |
| cosopt | New Drug Application | 2023-09-05 |
| cosopt pf | New Drug Application | 2024-01-08 |
| dorzolamide and timolol | ANDA | 2019-11-15 |
| dorzolamide hcl | ANDA | 2022-12-31 |
| dorzolamide hcl /timolol maleate | ANDA | 2013-01-29 |
| dorzolamide hcl and timolol maleate | ANDA | 2018-02-13 |
| dorzolamide hydrochloride | ANDA | 2024-01-26 |
| dorzolamide hydrochloride and timolol maleate | ANDA | 2024-01-26 |
| dorzolamide hydrochloride and timolol maleate ophthalmic | ANDA | 2023-11-13 |
Show 11 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 3 | 2 | 8 | 16 | 7 | 36 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 4 | 9 | 17 | 3 | 34 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 5 | 5 | 17 | 5 | 31 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | — | 1 | — | 2 |
| Exfoliation syndrome | D017889 | EFO_0004235 | — | — | — | — | 1 | 1 | 2 |
| Retinal degeneration | D012162 | HP_0001105 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | 2 | 1 | — | 1 | 3 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 2 | 1 | — | — | 2 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 2 | 2 |
| Retinoschisis | D041441 | — | H33.10 | — | — | — | — | 1 | 1 |
| Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | — | 1 | 1 |
| Scleral buckling | D012591 | — | — | — | — | — | — | 1 | 1 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | — | 1 | 1 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dorzolamide |
| INN | dorzolamide |
| Description | Dorzolamide is 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antihypertensive agent and an antiglaucoma drug. It is a sulfonamide and a member of thiophenes. |
| Classification | Small molecule |
| Drug class | carbonic anhydrase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 120279-96-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL218490 |
| ChEBI ID | 4702 |
| PubChem CID | 5284549 |
| DrugBank | DB00869 |
| UNII ID | 9JDX055TW1 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Dorzolamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Dorzolamide
+
Timolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,195 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,151 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use